KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
26 hedge funds and large institutions have $51.3M invested in KalVista Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
4% more funds holding
Funds holding: 25 → 26 (+1)
1.72% less ownership
Funds ownership: 60.21% → 58.49% (-1.7%)
17% less capital invested
Capital invested by funds: $61.6M → $51.3M (-$10.3M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
+$486K |
| 2 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$193K |
| 3 |
SIM
Spark Investment Management
New York
|
+$118K |
| 4 |
BlackRock
New York
|
+$96K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$49.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.91M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$385K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$159K |
| 4 |
JP Morgan Chase
New York
|
-$121K |
| 5 |
Renaissance Technologies
New York
|
-$68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
26
Advisor Group
Phoenix,
Arizona
| $1K | +$883 | +100 | New |
|
|
27
DZ Bank
Frankfurt Am Main,
Germany
| – | -$385K | -40,636 | Closed |
|
28
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$5K | -503 | Closed |
|
KALV Hedge Fund Activity: Q2 2018 in Review
26 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2018, worth a combined $51.3M — down 17% from $61.6M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KALV positions and 2 closed out — a net gain of 1 holder — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Telemetry Investments, opening a new position worth an estimated $486K. The largest seller was Millennium Management, cutting an estimated $1.91M.
- 26 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2018, up from 25 in Q1 2018.
- Funds reported $51.3M of KalVista Pharmaceuticals stock for Q2 2018, down 17% quarter-over-quarter.
- 3 funds opened new KalVista Pharmaceuticals positions in Q2 2018 and 2 closed out, a net change of +1 holder.
- The largest KalVista Pharmaceuticals buyer in Q2 2018 was Telemetry Investments, an estimated $486K added.
- The largest KalVista Pharmaceuticals seller in Q2 2018 was Millennium Management, an estimated $1.91M sold.
Based on aggregated 13F filings for Q2 2018.